三月 2026
- Home
- Zymeworks
三月 2026的Zymeworks市场份额分析
Zymeworks Inc. is a publicly held biotechnology company based in Vancouver,
British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure.
Zymeworks(包含公司地区分支机构)
查看更多网站流量和参与度信息- zymeworks.com
Zymeworks收入截至 三月 2026为 25M - 50M
Zymeworks主要域名产生的收入
3 年中Zymeworks主要域名的收入
Zymeworks主要域名的收入
Zymeworks热门域名的总访问量
了解Zymeworks市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
Zymeworks热门域名的平均访问时长
分析Zymeworks参与度指标。
过去 3 个月的平均访问时长
子公司明细
Zymeworks热门域名的平均页面浏览量
了解Zymeworks如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
Zymeworks 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻Zymeworks attends event AACR 2026.Zymeworks presents new preclinical data at AACR 2026 highlighting broad antibody-drug conjugate programs including novel ras-targeting platform.
四月 17, 2026阅读更多
新闻Zymeworks hired Scott Platshon on Apr 9th '26.VANCOUVER, British Columbia, April 09, 2026 (GLOBE NEWSWIRE) - Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the full-time appointments of Dr. Adam Schayowitz and Mr. Scott Platshon as of April 9, 2026, from their previously interim roles.
四月 9, 2026阅读更多
新闻Zymeworks attended event AACR Oncology Industry Partnering Event on Jan 1st '26."We're looking forward to participate in the AACR Oncology Industry Partnering Event this year," said Adam Schayowitz, Ph.D., MBA, Executive Vice President and Head of Research & Development at Zymeworks.
四月 9, 2026阅读更多
查看 Zymeworks 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。